Tesamorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Some people carry their fat right out front — deep, firm belly fat that no amount of crunches touches. That’s visceral fat, the kind packed around your organs, and it’s the metabolically active stuff most tied to cardiometabolic risk. Tesamorelin is the one peptide here with real, FDA-grade human trials showing it shrinks exactly that.
Here’s what makes it elegant. Tesamorelin doesn’t slam synthetic growth hormone into your body from outside. It tells your own pituitary to make more of your own GH, in your own natural pulsing rhythm. Think of it as turning up a dimmer switch your body already owns. Because it works through your own pituitary, your natural feedback brakes still function — there’s an off-switch built into the system, which is a meaningfully smarter design than injecting raw GH with no governor.
The molecule is a synthetic copy of GHRH (growth-hormone-releasing hormone), the hypothalamic signal that fires those GH pulses. It was developed, trialed, and approved as a pharmaceutical — which is why the human evidence here is unusually strong for a peptide. You’re not extrapolating from a mouse. You’re reading two Phase 3 trials.
What does it do in my body?
Your pituitary doesn’t drip growth hormone steadily — it pulses it, mostly at night, in bursts. As you age those pulses flatten out (a shift sometimes called somatopause). Tesamorelin is a modified copy of GHRH, the hypothalamic hormone that triggers those pulses.
The clever part is the chemistry. Native GHRH gets chewed up within minutes by an enzyme called DPP-IV. Tesamorelin carries a trans-3-hexenoic acid cap on its front end that shields it from that enzyme, so it survives long enough to do its job. The result: restored pulsatile GH release and a rise in IGF-1 (insulin-like growth factor 1 — the downstream messenger that does much of GH’s actual work in tissue).
Why visceral fat specifically? Visceral adipose tissue is especially sensitive to GH-driven lipolysis (fat breakdown). Restoring more youthful GH pulsatility preferentially mobilizes that deep abdominal fat — which is exactly what the trials measured.
How can it help me?
- Where the science stands: Phase 3 (two pivotal trials, n>800) + 2026 meta-analysis of 5 RCTs — part of a deep ~25-RCT human corpus (full HIV-lipodystrophy phase-3 set, NAFLD-in-HIV liver trials, and cognition trials)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The trial side-effect profile is well characterized — an advantage of having real Phase 3 data.
Most-reported in trials: arthralgia (joint pain), myalgia (muscle pain), paresthesia (tingling/numbness), peripheral edema (mild swelling in hands/feet/ankles), and injection-site reactions. Serious adverse events ran under 4% at 26 weeks. Most of these are dose-related GH/IGF-1 effects and tend to ease with time or a small dose reduction.
Practical management:
- Fluid/joint effects: mild edema and joint achiness usually settle within the first weeks; lowering the dose or spacing injections helps if they persist.
- Glucose/IGF-1: trials showed small HbA1c rises (~0.1–0.2%). If you’re insulin-resistant or diabetic, periodic glucose/HbA1c monitoring is sensible — this is a GH-axis tool.
- Anti-drug antibodies: roughly half of Phase 3 patients developed ADAs by 26 weeks; in the trials this didn’t blunt efficacy.
- Not permanent: stop, and visceral fat re-accumulates over months. It’s a tool that works while you use it — pair it with the lifestyle levers (sleep, movement, real food) to hold the result.
Practical contraindications to know: active malignancy (GH/IGF-1 can theoretically support tumor growth), pituitary tumors or recent head/neck radiation, and pregnancy (label Category X). These are the situations where the GH-axis mechanism argues for caution.
Regulatory status: FDA-approved as Egrifta (2010) and reformulated as Egrifta SV (2019) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The pharmaceutical product runs $3,000+/month. The research-chemical form sold by vendors like Alyve is the same molecule, sold research-use-only (“not for human consumption”) — which is precisely why the off-label and self-directed community uses the research-grade route at a fraction of the price. Tesamorelin is not on the WADA prohibited list as a named substance the way some secretagogues are, but GH-releasing peptides as a class fall under S2 — relevant only to tested athletes.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution math (objective): 10 mg ÷ 2 ml = 5 mg/ml = 5,000 mcg/ml. For 1 mg (1,000 mcg): 1,000 ÷ 5,000 = 0.2 ml = 20 units on a U-100 syringe. Alyve sells 10 ml bacteriostatic water (~$8) for reconstitution.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Pharmaceutical (FDA-label) dose: 2 mg subcutaneous, once daily, typically at night.
Community / practitioner-convention protocol (a commonly used practitioner protocol, April 2026):
- 10 mg vial, reconstitute with 2 ml bacteriostatic water
- Draw 1 mg = 0.2 ml = 20 units on a U-100 insulin syringe
- AM/PM dosing, 5 days on / 2 off, 8-week block, then a break
Where experts differ: the label dosed 2 mg once daily; the popular community split runs 1 mg AM and 1 mg PM (so up to 2 mg/day total) on a 5-on/2-off schedule. The total daily dose lands near the label, but the timing differs. Some users prefer a single PM dose to mirror the natural nighttime GH pulse and the trial protocol; others like the split for convenience. IGF-1 elevation has a ceiling, so chasing higher per-injection doses isn’t where the value is — consistency over a full block is.
What should I avoid combining — and what's synergistic?
Stacking. Tesamorelin pairs naturally with a GH-secretagogue like ipamorelin (GHRH analog + GHRP work on two different levers of the same pulse), and it slots into broader fat-loss and longevity stacks. In Dr. Jones’s “three hands of aging” framing, tesamorelin sits adjacent to the metabolic and GH-signaling hand; many users run it alongside a mitochondrial peptide like MOTS-c and a repair peptide like GHK-Cu.
How can I buy this?
- Product: Tesamorelin 10mg — $74.00 (on sale, regular $92.00) — IN STOCK
- COA: 99.46% purity, lot TES927, identity confirmed by Freedom Diagnostics Testing (independent 3rd party; HPLC-UV purity + LC-MS identity; net content 9.08 mg)
- Specs: CAS 218949-48-5; C221H366N72O67S; MW ~5135.9 g/mol; white lyophilized powder; store −20°C (note: 218949-48-5 is the free base; CAS 901758-09-6 refers to the acetate salt form — both are valid identifiers depending on salt form. PubChem CID 16137828.)
- Alyve’s own copy is restrained — they describe it as “studied for endocrine-axis signaling and somatotroph function research” and make no fat-loss claims.
The trust angle: roughly a quarter of gray-market peptides are underdosed, mislabeled, or TFA-salt-contaminated. Tesamorelin’s third-party COA at 99.46% with confirmed identity is the verified-clean tier — that verification is the whole point.
CTA: Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. That’s how committed users buy a multi-month block.
Tesamorelin is also available from US Pure Peptides — use code OHM20 for 20% off. US-manufactured, ISO 17025-accredited third-party COA testing on every batch, free bacteriostatic water included.
Tesamorelin is also available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Tesamorelin is the rare peptide in this catalog with FDA-grade human randomized-trial data behind it — pivotal Phase 3 RCTs plus a 2026 meta-analysis, all pointing the same direction: it shrinks visceral fat by nudging your own pituitary to release your own growth hormone, in your own natural rhythm. It is FDA-approved as Egrifta for HIV-associated lipodystrophy; the same molecule is sold research-use-only by vendors like Alyve. This article gives you the full picture so you can decide for yourself.
| Class | Synthetic 44-amino-acid GHRH analog (growth-hormone-releasing hormone — the brain signal that tells your pituitary to make GH) |
| Mechanism (one line) | Binds the GHRH receptor on the pituitary → restores natural pulsatile GH release → raises IGF-1 → preferentially burns visceral fat |
| Route | Subcutaneous injection |
| Half-life | ~26–38 min |
| Evidence base | Phase 3 (two pivotal trials, n>800) + 2026 meta-analysis of 5 RCTs — part of a deep ~25-RCT human corpus (full HIV-lipodystrophy phase-3 set, NAFLD-in-HIV liver trials, and cognition trials) |
| Regulatory status | FDA-approved 2010 (Egrifta), reformulated 2019 (Egrifta SV) — for HIV-associated lipodystrophy. Research-chemical form is the same molecule, sold for research use |
| Alyve product | Tesamorelin 10mg — $74.00 (sale, reg. $92) — COA 99.46% purity (lot TES927) — IN STOCK |
| Primary use case | Visceral (deep-belly) fat reduction; growing interest in liver fat and cognition |
What it is
Some people carry their fat right out front — deep, firm belly fat that no amount of crunches touches. That’s visceral fat, the kind packed around your organs, and it’s the metabolically active stuff most tied to cardiometabolic risk. Tesamorelin is the one peptide here with real, FDA-grade human trials showing it shrinks exactly that.
Here’s what makes it elegant. Tesamorelin doesn’t slam synthetic growth hormone into your body from outside. It tells your own pituitary to make more of your own GH, in your own natural pulsing rhythm. Think of it as turning up a dimmer switch your body already owns. Because it works through your own pituitary, your natural feedback brakes still function — there’s an off-switch built into the system, which is a meaningfully smarter design than injecting raw GH with no governor.
The molecule is a synthetic copy of GHRH (growth-hormone-releasing hormone), the hypothalamic signal that fires those GH pulses. It was developed, trialed, and approved as a pharmaceutical — which is why the human evidence here is unusually strong for a peptide. You’re not extrapolating from a mouse. You’re reading two Phase 3 trials.
How it works
Your pituitary doesn’t drip growth hormone steadily — it pulses it, mostly at night, in bursts. As you age those pulses flatten out (a shift sometimes called somatopause). Tesamorelin is a modified copy of GHRH, the hypothalamic hormone that triggers those pulses.
The clever part is the chemistry. Native GHRH gets chewed up within minutes by an enzyme called DPP-IV. Tesamorelin carries a trans-3-hexenoic acid cap on its front end that shields it from that enzyme, so it survives long enough to do its job. The result: restored pulsatile GH release and a rise in IGF-1 (insulin-like growth factor 1 — the downstream messenger that does much of GH’s actual work in tissue).
Why visceral fat specifically? Visceral adipose tissue is especially sensitive to GH-driven lipolysis (fat breakdown). Restoring more youthful GH pulsatility preferentially mobilizes that deep abdominal fat — which is exactly what the trials measured.
What the research shows
This is the rare peptide where the headline evidence is human and randomized. The full tesamorelin corpus runs to roughly 25 randomized controlled trials — the complete HIV-lipodystrophy phase-3 program (Falutz and Grinspoon teams), a cluster of NAFLD/liver-fat trials, and a growing cognition line. The summary below is the source-of-truth read of that trial set.
** The pivotal trials.** Two Phase 3 double-blind placebo-controlled RCTs (pooled n=806) showed tesamorelin cut visceral adipose tissue by about −15.4% at 26 weeks, holding at −17.5% through 52 weeks in continuers, alongside drops in triglycerides and the cholesterol/HDL ratio. Glucose wasn’t meaningfully harmed. A second pivotal trial (n=404) found −10.9% VAT at 6 months rising to roughly −18% at 12 months.
** The 2026 meta-analysis** pooled 5 RCTs: visceral fat down ~27.7 cm², trunk fat −1.18 kg, hepatic (liver) fat −4.28%, waist −1.61 cm, and — notably — lean mass UP +1.42 kg. That’s a consistent, replicated signal: less visceral and liver fat, more lean mass.
** Liver / NAFLD.** A rigorous 12-month RCT in 61 patients with fatty liver showed reduced hepatic fat and slower fibrosis progression, with transcriptomic and proteomic sub-studies showing down-regulated inflammation and immune activation. The same Grinspoon/Stanley/Fourman group built this into a full NAFLD-in-HIV program — parallel reductions in circulating immune-activation markers alongside the hepatic effects, plus targeted proteomic/transcriptomic and fibrosis-predictor sub-studies. This replicated liver-fat signal is the basis for the growing interest in tesamorelin for metabolic/fatty-liver applications.
** Cognition.** A 20-week RCT in 152 older adults (76 healthy, 61 with mild cognitive impairment) found improved executive function (p=0.005) and a verbal-memory trend; a companion brain-imaging RCT linked GHRH treatment to favorable changes in brain GABA levels in MCI and healthy aging. The cognition line is now extending into the approved population: a multicenter phase-2 RCT tested tesamorelin on neurocognitive impairment in people with HIV and abdominal obesity. GHRH analogs reaching the brain and affecting executive function and neurochemistry is an exciting, actively-expanding signal worth watching.
Where the data is concentrated. The pivotal fat-loss and NAFLD trials were run in HIV-associated lipodystrophy populations (the approved indication), and the cognition line, while now more than one study, remains small. So general anti-aging, body-recomposition, and metabolic-syndrome use draws on the mechanism plus this HIV-population trial base rather than dedicated trials in those exact populations. The mechanism — restored pulsatile GH and visceral-fat lipolysis — is the same biology in anyone; the broader-population trials simply haven’t all been run yet. That’s where a bleeding-edge compound sits: strong human core, expanding edges.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Pharmaceutical (FDA-label) dose: 2 mg subcutaneous, once daily, typically at night.
Community / practitioner-convention protocol (a commonly used practitioner protocol, April 2026):
- 10 mg vial, reconstitute with 2 ml bacteriostatic water
- Draw 1 mg = 0.2 ml = 20 units on a U-100 insulin syringe
- AM/PM dosing, 5 days on / 2 off, 8-week block, then a break
Reconstitution math (objective): 10 mg ÷ 2 ml = 5 mg/ml = 5,000 mcg/ml. For 1 mg (1,000 mcg): 1,000 ÷ 5,000 = 0.2 ml = 20 units on a U-100 syringe. Alyve sells 10 ml bacteriostatic water (~$8) for reconstitution.
Where experts differ: the label dosed 2 mg once daily; the popular community split runs 1 mg AM and 1 mg PM (so up to 2 mg/day total) on a 5-on/2-off schedule. The total daily dose lands near the label, but the timing differs. Some users prefer a single PM dose to mirror the natural nighttime GH pulse and the trial protocol; others like the split for convenience. IGF-1 elevation has a ceiling, so chasing higher per-injection doses isn’t where the value is — consistency over a full block is.
Stacking. Tesamorelin pairs naturally with a GH-secretagogue like ipamorelin (GHRH analog + GHRP work on two different levers of the same pulse), and it slots into broader fat-loss and longevity stacks. In Dr. Jones’s “three hands of aging” framing, tesamorelin sits adjacent to the metabolic and GH-signaling hand; many users run it alongside a mitochondrial peptide like MOTS-c and a repair peptide like GHK-Cu.
Side effects & management
The trial side-effect profile is well characterized — an advantage of having real Phase 3 data.
Most-reported in trials: arthralgia (joint pain), myalgia (muscle pain), paresthesia (tingling/numbness), peripheral edema (mild swelling in hands/feet/ankles), and injection-site reactions. Serious adverse events ran under 4% at 26 weeks. Most of these are dose-related GH/IGF-1 effects and tend to ease with time or a small dose reduction.
Practical management:
- Fluid/joint effects: mild edema and joint achiness usually settle within the first weeks; lowering the dose or spacing injections helps if they persist.
- Glucose/IGF-1: trials showed small HbA1c rises (~0.1–0.2%). If you’re insulin-resistant or diabetic, periodic glucose/HbA1c monitoring is sensible — this is a GH-axis tool.
- Anti-drug antibodies: roughly half of Phase 3 patients developed ADAs by 26 weeks; in the trials this didn’t blunt efficacy.
- Not permanent: stop, and visceral fat re-accumulates over months. It’s a tool that works while you use it — pair it with the lifestyle levers (sleep, movement, real food) to hold the result.
Practical contraindications to know: active malignancy (GH/IGF-1 can theoretically support tumor growth), pituitary tumors or recent head/neck radiation, and pregnancy (label Category X). These are the situations where the GH-axis mechanism argues for caution.
The IGF-1 mitogen concern — the honest read for healthy off-label users
Tesamorelin’s actual safety record sits inside one population on one protocol: HIV-associated lipodystrophy, 26 weeks + a 1-year extension. That’s the studied use. Healthy-adult off-label use for body composition, anti-aging, or long-term recomposition is data-extrapolation, not data-validated — and the mechanism worth understanding before you extrapolate is IGF-1 biology.
Tesamorelin works by stimulating pituitary GH release. Sustained GH elevation drives sustained IGF-1 elevation. IGF-1 is a mitogen — its job in cell biology is to tell cells to grow and divide. That’s the desired effect in muscle and connective tissue. It’s also the unwanted effect in any tissue carrying elevated proliferative potential — meaning any incipient or established malignancy. Population-level epidemiology (the seminal Lancet meta-analysis is Renehan et al. 2004, PMID 15110491; updated across the 2000s–2010s in JNCI and Endocrine Reviews) shows associations between upper-tertile IGF-1 levels and increased risk of certain cancers (colorectal, breast, prostate at the strongest end of the signal).
The honest read: this is epidemiologic correlation in observational populations, not a proven cause-effect mechanism for tesamorelin-driven IGF-1 elevation in healthy adults. The concern is real, sourced, and not dismissable; it’s also not proven. For an OHM customer making a real decision, the takeaway is:
- Get baseline + on-schedule IGF-1 labs if you’re using tesamorelin off-label. Don’t drift into the upper tertile without knowing it.
- Skip the “more is better” framing. The trial dose was 2 mg/day, and the effect plateaus. Pushing higher doses extracts no extra fat-loss benefit and pushes IGF-1 further up the curve where the epidemiologic risk lives.
- Cancer-screening cadence matters. If you’re going to run a sustained GH-axis intervention, age-appropriate cancer screening (colonoscopy, mammogram, PSA per your risk profile) isn’t optional — it’s the matched-frequency monitoring for the matched risk.
Stacking with retatrutide — unstudied, theoretically concerning
Online forum protocols increasingly combine tesamorelin with Retatrutide for “longevity + body recomp.” OHM’s honest position: the combination has zero published human studies. No Phase 1, no Phase 2, no pharmacokinetic data, no interaction profile, no long-term safety. It exists only in forum protocols posted by users assuming “drug A + drug B = sum of their individual effects.” Real pharmacology doesn’t work that way.
Three specific reasons the stack warrants caution beyond “it’s unstudied”:
- IGF-1 mitogen concern compounds. Tesamorelin alone drives sustained IGF-1 elevation. The IGF-1 / cancer epidemiologic signal sits on the upper tertile of population IGF-1. Adding any longevity-stack intervention that further extends GH-axis stimulation pushes you further into that tertile, for longer — that’s mechanism-extrapolation, not trial-confirmed, but the direction is unambiguous.
- Both drugs touch metabolism in different directions. Tesamorelin via GH/IGF-1 (anabolic-leaning); retatrutide via GLP-1+GIP+glucagon (catabolic-leaning, glucagon-mediated thermogenesis). The net effect on insulin sensitivity, lean-mass preservation, hepatic glucose output, and the IGF-1 trajectory under sustained co-administration is unstudied.
- The studied population for tesamorelin is HIV-lipodystrophy on a defined protocol. Healthy-adult use is already off-label data-extrapolation; adding an investigational triple-agonist on top is double extrapolation. Forum testimonials don’t substitute for that data — they aggregate the people who didn’t have problems.
The OHM customer-facing position (per the Pep-as-reporter doctrine): the combination is generally not advised because of the unstudied PK + the compounded IGF-1 concern; some longevity-focused practitioners run it with elevated IGF-1 monitoring and cancer-screening cadence — talk to a prescriber familiar with this specific stack before considering it.
Regulatory status
FDA-approved as Egrifta (2010) and reformulated as Egrifta SV (2019) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The pharmaceutical product runs $3,000+/month. The research-chemical form sold by vendors like Alyve is the same molecule, sold research-use-only (“not for human consumption”) — which is precisely why the off-label and self-directed community uses the research-grade route at a fraction of the price. Tesamorelin is not on the WADA prohibited list as a named substance the way some secretagogues are, but GH-releasing peptides as a class fall under S2 — relevant only to tested athletes.
The Alyve product
- Product: Tesamorelin 10mg — $74.00 (on sale, regular $92.00) — IN STOCK
- COA: 99.46% purity, lot TES927, identity confirmed by Freedom Diagnostics Testing (independent 3rd party; HPLC-UV purity + LC-MS identity; net content 9.08 mg)
- Specs: CAS 218949-48-5; C221H366N72O67S; MW ~5135.9 g/mol; white lyophilized powder; store −20°C (note: 218949-48-5 is the free base; CAS 901758-09-6 refers to the acetate salt form — both are valid identifiers depending on salt form. PubChem CID 16137828.)
- Alyve’s own copy is restrained — they describe it as “studied for endocrine-axis signaling and somatotroph function research” and make no fat-loss claims.
The trust angle: roughly a quarter of gray-market peptides are underdosed, mislabeled, or TFA-salt-contaminated. Tesamorelin’s third-party COA at 99.46% with confirmed identity is the verified-clean tier — that verification is the whole point.
CTA: Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. That’s how committed users buy a multi-month block.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.
| Field | Value |
|---|---|
| Molecular formula | C221H366N72O67S (PubChem CID 16137828) |
| Average MW | ~5135.9 g/mol |
| CAS | 218949-48-5 (free base); 901758-09-6 (acetate salt) |
| Sequence | trans-3-hexenoyl-GHRH(1-44)-NH2 (hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2) |
| HPLC purity criterion | RP-HPLC main peak ≥98.0%, no single impurity >0.5% |
| MS identity | ESI-MS [M+H]+ = 5135.89 ± 2.0 Da; N-terminal trans-3-hexenoyl confirmed by MS/MS (>95% modified) |
| Counterion / net peptide | Acetate ≤8%, TFA ≤0.5%; peptide content ≥90% by AAA |
| Storage / reconstitution | Lyophilized −20°C to −80°C desiccated, amber vial (24–36 mo); reconstitute 2 mg vial with ~2 mL bacteriostatic water, gentle swirl; reconstituted 2–8°C up to 14 days; ≤3 freeze-thaw cycles |
| Degradation / stability | Met (residue 27 in the GHRH numbering) oxidation; reconstituted solution stable ~7–14 days at 4°C (superior to native GHRH); endotoxin <1.0 EU/mg |
Primary-literature citation leads (PeptideBiologix; confirm before citing): Falutz et al. JAMA 2010;304(4):453-61; Stanley et al. JAMA 2014;312(4):380-9 (both already represented in this article’s Sources). Note: the source page’s quick-reference header and molecular-properties table disagree internally on which CAS/MW to list — the verified split above (free base vs acetate) resolves it.
Sources
- : 41545261 — 2026 meta-analysis of 5 RCTs
- : 20554713 — Pooled Phase 3 (n=806)
- : 20101189 — Phase 3 RCT (n=404)
- : 32701508 — Hepatic transcriptomics RCT
- : 33852720 — Immune activation RCT
- : 20943777 — GH pulsatility / mechanism, healthy men
- : 21265979 — Systematic review, GH-axis treatments
- : 21668043 — Drug review (Dhillon)
- : 22869065 — Baker 2012 cognition RCT
- : 23689947 — Friedman 2013, GHRH/brain-GABA RCT (JAMA Neurol)
- : 39813152 — Ellis 2025, tesamorelin neurocognition in HIV phase-2 RCT (J Infect Dis)
- Alyve product page — https://alyvepeptides.com/product/tesamorelin-10mg/
- (0019 exhaustive corpus, 118 records / ~25 RCTs),
Sources & references
- : 41545261 — 2026 meta-analysis of 5 RCTs
- : 20554713 — Pooled Phase 3 (n=806)
- : 20101189 — Phase 3 RCT (n=404)
- : 32701508 — Hepatic transcriptomics RCT
- : 33852720 — Immune activation RCT
- : 20943777 — GH pulsatility / mechanism, healthy men
- : 21265979 — Systematic review, GH-axis treatments
- : 21668043 — Drug review (Dhillon)
- : 22869065 — Baker 2012 cognition RCT
- : 23689947 — Friedman 2013, GHRH/brain-GABA RCT (JAMA Neurol)
- : 39813152 — Ellis 2025, tesamorelin neurocognition in HIV phase-2 RCT (J Infect Dis)
- Alyve product page — https://alyvepeptides.com/product/tesamorelin-10mg/
- (0019 exhaustive corpus, 118 records / ~25 RCTs),
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout Last updated: 2026-07-10 Cross-refs:
*cjc-1295-no-dac*·[Ipamorelin](/peptides/ipamorelin/)·[CJC-1295 / Ipamorelin](/peptides/cjc-1295-ipamorelin/)
Who reports the strongest results
People with stubborn visceral and deep abdominal fat that hasn’t responded to diet, training, or other peptide protocols. Tesamorelin is the community’s go-to specifically for belly fat — it is the only FDA-approved GHRH with labeling for visceral fat reduction, and the community treats this as meaningful signal.
What the community actually says
The abdominal fat effect — concrete and documented
Community results for belly fat reduction are the most concrete body-measurement data in the GH peptide space:
- judgetoo’s 12-week log: 37% reduction in visceral adipose tissue measured by imaging
- mainelee’s tape measurement: 7.5 inches lost from belly circumference across 12 weeks; weekly measurements logged
- Multiple accounts describe fat in the lower abdomen that “diet and exercise never touched” responding within 8–12 weeks
- The target tissue is visceral fat (internal, surrounding organs) first, then subcutaneous — users with pure subcutaneous belly fat may notice later results than those with high VAT
The rebound reality — critical to set expectations
The community is honest about this: visceral fat returns when tesamorelin is stopped.
Most users document significant regain within 3–6 months of discontinuation. Community analogy: “It’s like a GLP-1 for belly fat — it works while you use it, it comes back when you stop.”
This drives two strategies:
- Long-term/continuous use with periodic dose holidays — accepted as an ongoing intervention, not a temporary one
- Cycled use (12 weeks on / 12 weeks off) — accepts some cyclical rebound; manages cost and GH exposure
Community consensus: the rebound is not a failure mode — it’s inherent to the mechanism. Tesamorelin works best when treated as part of an ongoing metabolic optimization strategy, not a one-time fix.
Protocol as used by the community
Dose: 1–2 mg SubQ daily or 5 days on/2 off Starting: Most users begin at 1 mg/day Timing: Pre-sleep primary; fasted morning secondary Gold standard stack: Tesamorelin + Ipamorelin — ipamorelin amplifies the GH pulse that tesamorelin triggers; community considers this the optimal combination for visceral fat reduction
Side effects
More pronounced than sermorelin; manageable.
- Water retention — early; more significant than other GHRHs; resolves weeks 2–4
- Joint aches / carpal tunnel symptoms — more frequently reported than CJC-1295; GH fluid shifts; manageable with dose adjustment
- Tingling in extremities — moderate incidence
- Glucose elevation — GH’s insulin-antagonistic effect is more pronounced at tesamorelin’s effective doses; monitoring recommended for metabolically at-risk users
- Injection site reactions — higher incidence than other GHRHs per community reports
How tesamorelin compares to CJC-1295 + ipamorelin for belly fat
Community view: tesamorelin is more targeted to visceral/abdominal fat specifically. CJC-1295 + ipamorelin produces more systemic body composition changes (lean mass + fat). For someone whose primary goal is visceral fat, tesamorelin is the better tool. For overall body composition optimization, CJC-1295 + ipamorelin is the standard. Many users run both at different phases.
Cross-references
*cjc-1295-no-dac*— alternative GHRH with broader body composition effects[Ipamorelin](/peptides/ipamorelin/)— standard GHRP pairing with tesamorelin[CJC-1295 / Ipamorelin](/peptides/cjc-1295-ipamorelin/)— the combination for broader GH optimization
Commercial note
Tesamorelin is available through Alyve — use code OHM-15 at checkout for 15% off.
Stacking with 5-Amino-1MQ
Community experience with this pairing is effectively non-existent as of 2026. The question comes up frequently in theory, but documented n=1 logs are absent.
The theoretical synergy
5-Amino-1MQ works by inhibiting NNMT (nicotinamide N-methyltransferase), which increases intracellular NAD+ availability and upregulates mitochondrial fat oxidation — see [5-Amino-1MQ](/peptides/5-amino-1mq/) for mechanism detail. Tesamorelin targets visceral fat via GH-mediated lipolysis and preferential mobilization of abdominal adipose tissue.
The hypothetical stack logic:
- Tesamorelin releases the fat from visceral stores
- 5-Amino-1MQ optimizes the cellular machinery to burn it efficiently
Community members who understand both mechanisms consistently describe this as “complementary pathways” — one mobilizes, one oxidizes. The question is whether that theoretical synergy translates to measurable real-world advantage over tesamorelin alone or tesamorelin + ipamorelin.
Why the community hasn’t tested this yet
- Tesamorelin + ipamorelin is already effective — the documented visceral fat results (7.5-inch waist reductions, 37% VAT drops) leave little room for “this wasn’t enough” complaints that would drive experimentation
- 5-Amino-1MQ supply chain maturity — the compound only entered broader peptide vendor catalogs in late 2023; tesamorelin community protocols predate this availability window by years
- Cost — both are premium peptides; stacking them crosses into high monthly spend territory without documented proof of additive benefit
The more common comparison: tesamorelin + ipamorelin vs. tesamorelin + 5-Amino-1MQ
Community standard for visceral fat: tesamorelin 1 mg + ipamorelin 200–300 mcg daily. This pairing has hundreds of documented logs. The ipamorelin amplifies the GH pulse that tesamorelin triggers — direct pathway synergy with clear mechanistic logic and proven community outcomes.
For someone considering 5-Amino-1MQ instead of ipamorelin as the tesamorelin pairing:
- Ipamorelin = amplifies the existing GH signal; works within the same hormonal axis; established safety profile in combination
- 5-Amino-1MQ = independent mitochondrial pathway; no documented interaction data with GH secretagogues; may offer broader metabolic optimization beyond fat loss (NAD+ effects touch inflammation, aging pathways — see
[5-Amino-1MQ](/peptides/5-amino-1mq/))
The functional-medicine practitioners in the OHM network who work with both compounds tend to introduce 5-Amino-1MQ as a metabolic foundation layer (run continuously or in 8–12 week cycles) and layer tesamorelin on top when visceral fat is the specific target — rather than treating them as direct alternatives in a pairing decision.
If attempting this stack: monitoring priorities
Anyone running tesamorelin + 5-Amino-1MQ as an n=1 experiment should track:
- Fasting glucose and HbA1c — tesamorelin’s GH effects are insulin-antagonistic; 5-Amino-1MQ’s NAD+ upregulation theoretically improves insulin sensitivity, but the net effect in combination is unknown. GH peptides + any metabolic modulator = glucose monitoring is non-negotiable.
- Waist circumference (weekly tape measurements at navel) — the documented outcome metric for tesamorelin efficacy
- Subjective energy / recovery — 5-Amino-1MQ’s NAD+ effects should produce noticeable changes in fatigue resilience and workout recovery within 3–4 weeks if the compound is working; this separates the 5-Amino-1MQ contribution from tesamorelin’s body composition effects
If someone completes a 12-week log with this pairing and documents it publicly, that report would be high-value community data. As of now, it doesn’t exist.
Cross-references
[5-Amino-1MQ](/peptides/5-amino-1mq/)— mechanism, dosing, and standalone community experience[Ipamorelin](/peptides/ipamorelin/)— the established tesamorelin pairing with documented synergy[CJC-1295 / Ipamorelin](/peptides/cjc-1295-ipamorelin/)— alternative GH secretagogue stack for broader body composition goals